⏳ Fetching live dividend data...
Home › Calculator › CYAD Dividend Calculator 2026
Celyad Oncology S.A. · NASDAQ
Price: $0.47 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in CYAD → $164.73M in 10 years · $56,811.16/month
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phase 1b trials for patients with metastatic colorectal cancer. Another allogeneic, shRNA-based CAR-T candidate, CYAD-211, is in Phase 1 for individuals suffering from relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T therapy, is being evaluated in Phase 1 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, Celyad is developing CYAD-203. This is a non-gene edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 (IL-18) alongside natural killer group 2D ligands (NKG2D), targeting solid tumors. Celyad has also forged strategic alliances. It holds a licensing agreement with Novartis International AG concerning US patents for allogeneic CAR-T cell technology. Furthermore, the company has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to establish a second non-gene-edited allogeneic platform. Founded in 2004, the company was initially named Celyad SA, but rebranded to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CYAD position with:
Real after-tax yield depends on where you live and how you hold CYAD.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 425.53% | 422.73% | $42,553 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 361.70% | 358.90% | $36,170 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 340.42% | 337.62% | $34,042 / yr |
| 🇬🇧 UK ISA | 0% | 425.53% | 422.73% | $42,553 / yr |
| 🇬🇧 UK Taxable | 8.75% | 388.30% | 385.50% | $38,830 / yr |
| 🇨🇦 TFSA | 0% | 425.53% | 422.73% | $42,553 / yr |
| 🇨🇦 CA Taxable | 25% | 319.15% | 316.35% | $31,915 / yr |
| 🇦🇺 Super (pension) | 15% | 361.70% | 358.90% | $36,170 / yr |
| 🇦🇺 AU Taxable | 30% | 297.87% | 295.07% | $29,787 / yr |
| 🇩🇪 DE Taxable | 26.375% | 313.30% | 310.50% | $31,330 / yr |
| 🇫🇷 FR Taxable | 30% | 297.87% | 295.07% | $29,787 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CYAD pays quarterly — 4 times per year. Next ex-div: TBD.
How CYAD compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CYAD sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CYAD dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Celyad Oncology S.A. (CYAD) is currently trading at $0.47, trading near its 52-week low. The current dividend yield is 425.53% based on an annual payout of $2.00 per share.
Celyad Oncology S.A. (CYAD) is a healthcare stock currently trading at $0.47 with a dividend yield of 425.53%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →